Baxter International (0QK8) AI Stock Analysis

Baxter International

(LSE:0QK8)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring clinical-care demandBaxter’s mix of disposable consumables, IV solutions and renal-therapy products supports repeat purchasing as patients continue receiving treatment. This recurring clinical-use model can provide durable demand and reduce reliance on occasional capital-equipment purchases.

Negative Factors

Persistent net lossesPersistent net losses show that Baxter’s positive EBITDA and revenue recovery have not yet translated into sustainable bottom-line profitability. Until earnings conversion improves, the company has less internally generated capacity to reduce debt, invest, or absorb operating setbacks.

Baxter International (0QK8) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $11.89B
Dividend Yield: 0.18%
Average Volume (3M): 4,988
Price to Earnings (P/E): -16.7
Beta (1Y): 1.64
Revenue Growth: 5.33%
EPS Growth: -164.67%
Country: UK
Employees: 37,500
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Baxter International Business Overview & Revenue Model

Company Description

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemo...

Baxter International Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-7.66%|Next Earnings Date:Feb 17, 2027

Earnings Call SentimentPositive

The call was broadly constructive and reflected improving execution, strong free cash flow, deleveraging progress, segment growth and raised full-year guidance. Management also highlighted ongoing challenges, including lower adjusted earnings, injectables and cephalosporin-related issues, lower margins, inflation, tariffs and several 2027 headwinds. Highlights significantly outweighed the lowlights, while management acknowledged that further work is required to improve consistency and execution.

Positive Updates

Quarterly Sales Growth Exceeded Expectations

Third-quarter global sales totaled approximately $3 billion, increasing 5% on both a reported and organic basis. Growth was broad-based, with every division contributing and both U.S. and international markets growing; Advanced Surgery, Drug Compounding and Infusion Systems were the largest contributors.

Negative Updates

Adjusted Earnings Declined Year-over-Year

Third-quarter adjusted earnings were $0.58 per diluted share, a decrease of 16% year-over-year. The decline reflected an expected higher effective tax rate because the prior-year quarter benefited from discrete tax items, including reserve releases, withholding taxes and other discrete tax benefits.

Company Guidance

For full year 2026, Baxter now expects total sales growth of 4% to 5% on a reported basis, with foreign exchange rates expected to contribute approximately 100 basis points to top line growth, reported sales including a headwind of approximately $25 million from MSA revenues from Vantive, representing approximately 30 basis points of impact on reported growth, and organic sales growth of 3% to 4%; MPT organic sales are expected to grow low to mid-single digits and HST organic sales low single digits. TSA income and other Vantive-related reimbursements are expected to range between $165 million to $175 million, adjusted operating margin is expected to be 13% to 14%, nonoperating expenses between $245 million to $255 million, the full year tax rate between 18.5% and 19.5%, diluted share count approximately 519 million shares, and adjusted earnings $2.05 to $2.15 per diluted share; Baxter expects a net leverage ratio of approximately 3x by year-end, Q4 growth around 5% and a similar magnitude of operating margin as Q3, while 2027 guidance will be provided in February.

Baxter International Risk Analysis

Baxter International disclosed 34 risk factors in its most recent earnings report. Baxter International reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Baxter International Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0QK8 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOLV	79Outperform	$13.84B	9.89	28.96%	―	-1.18%	277.21%
MDLN	69Neutral	$42.23B	37.35	5.45%	―	12.12%	-46.11%
ICUI	65Neutral	$4.10B	136.48	1.41%	―	-8.84%	―
BDX	63Neutral	$53.90B	59.60	3.79%	2.01%	-2.56%	-40.38%
TFX	55Neutral	$5.92B	-6.00	-31.83%	0.97%	-14.49%	-644.98%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0QK8 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0QK8	Baxter International Inc	23.86	5.97	33.35%
BDX	Becton, Dickinson and Co	198.60	61.33	44.68%
ICUI	ICU Medical	162.38	36.72	29.22%
TFX	Teleflex	140.67	17.63	14.33%
SOLV	Solventum Corporation	84.75	16.16	23.56%
MDLN	Medline, Inc. Class A	33.63	-7.37	-17.98%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Baxter International AI Stock Analysis